Get the Stockscreener App
23.51
2.25%
-0.566
Capricor Therapeutics Inc stock is traded at $23.51, with a volume of 1.33M.
It is down -2.25% in the last 24 hours and down -17.50% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$24.08
Open:
$24.125
24h Volume:
1.33M
Relative Volume:
1.15
Market Cap:
$1.36B
Revenue:
$11.13M
Net Income/Loss:
$-114.59M
P/E Ratio:
-10.17
EPS:
-2.313
Net Cash Flow:
$-113.96M
1W Performance:
-20.24%
1M Performance:
-17.50%
6M Performance:
-18.44%
1Y Performance:
+142.65%
1-Day Range:
$23.12
$24.25
1-Week Range:
$23.12
$30.93
52-Week Range:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
23.48 | 1.39B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
497.70 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
626.22 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
911.19 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.14 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.00 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Capricor’s positive 5-year data for DMD treatment comes with a regulatory catch – CAPR stock slides 11% - MSN
July meeting date set for FDA, developer to talk deramiocel for DMD - Muscular Dystrophy News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review - Stocktwits
Securities Class Action Lawsuit Filed Against Capricor Therapeuti - The National Law Review
Capricor CFO Bergmann sells $732k in shares By Investing.com - Investing.com Australia
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock By Investing.com - Investing.com Australia
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor Therapeutics Insiders Sold Shares Worth Over $1.5M - TradingView
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell 3000E Index - marketscreener.com
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your - The National Law Review
Capricor Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Litvack Frank - Moomoo
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell Microcap Index - marketscreener.com
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
Class Action Alert: Levi & Korsinsky Reminds Capricor (CAPR) Investors of September 15, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shar - The National Law Review
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action - The National Law Review
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting - Intellectia AI
Capricor Therapeutics Announces FDA Advisory Committee Meeting for Deramiocel Cell Therapy in Duchenne Muscular Dystrophy – Minichart - Minichart
Capricor Therapeutics to Face FDA Advisory Panel on BLA for Deramiocel; PDUFA Aug 22 - TradingView
[8-K] CAPRICOR THERAPEUTICS, INC. Reports Material Event - Stock Titan
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
What's Going On With Capricor Therapeutics Stock On Friday? - Benzinga
Capricor Therapeutics (CAPR) Reports Positive Long-Term Data for Deramiocel - GuruFocus
Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% - Stocktwits
Capricor Therapeutics, Inc. (CAPR) Stock: July FDA Review Tests Deramiocel Outlook - parameter.io
Capricor Therapeutics (CAPR) Faces 12% Decline Ahead of FDA Advi - GuruFocus
Capricor Therapeutics (CAPR) Seeks FDA Meeting for Cell Therapy Approval - GuruFocus
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout | AI
FDA schedules advisory meeting for Capricor’s DMD therapy By Investing.com - Investing.com India
Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set For August 22 - TradingView
Capricor Therapeutics Announces FDA Advisory Committee - GlobeNewswire
FDA panel to review Capricor’s Duchenne drug on July 29 - Stock Titan
Capricor faces FDA AdCom panel for Duchenne drug (CAPR:NASDAQ) - Seeking Alpha
Capricor reports five-year data for Duchenne therapy deramiocel By Investing.com - Investing.com Canada
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference - The Manila Times
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
1.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):